Materiały źródłowe

• #1 MenB vaccine – NHS

  https://www.nhs.uk/vaccinations/menb-vaccine/

  The MenB vaccine helps protect against meningococcal group B bacteria that can cause serious illnesses, including meningitis and sepsis. […] The MenB vaccine helps protect children against bacterial infections caused by meningococcal group B bacteria (MenB). […] MenB can cause serious illnesses, including: meningitis (an infection in the brain and spinal cord), septicaemia (blood poisoning), sepsis (a life-threatening reaction to an infection). […] The MenB vaccine works very well at protecting children against most types of meningococcal group B bacteria in the UK. […] Research has shown that the vaccine is very effective at preventing illnesses caused by these bacteria. […] Before the MenB vaccine was introduced, meningococcal group B bacteria were the biggest cause of meningitis and sepsis in the UK. […] Since the vaccine has been used in the UK, there has been a big drop in the number of young children getting MenB illnesses. […] The MenB vaccine does not protect against other causes of meningitis and sepsis, so it’s still important to be aware of the symptoms.

• #2 Meningitis B (MenB) vaccine | NHS inform

  https://www.nhsinform.scot/healthy-living/immunisation/vaccines/meningitis-b-menb-vaccine/

  The meningitis B (MenB) vaccine helps protect against meningitis and septicaemia (blood poisoning) caused by meningococcal bacteria B. […] MenB is now the cause of most cases of meningococcal disease in Scotland. Although this infection isn’t common, MenB is extremely serious and can lead to permanent disability and death. The meningococcal bacteria can also cause local outbreaks in nurseries, schools and universities. […] MenB infection is most common in babies and young children. This is because their immune systems aren’t yet fully developed to fight off infection. The highest number of cases are in babies around 5 months of age. […] The MenB vaccine is given as an injection and helps to protect babies against meningitis and septicaemia caused by meningococcal bacteria group B. […] The MenB vaccine is highly effective against serious infections caused by meningococcal group B bacteria. It’s also thought that it’s likely to provide some protection against other strains of meningococcal disease, including MenC.

• #3

  https://www.gov.uk/government/news/new-study-confirms-success-of-menb-vaccine-in-the-uk

  MenB vaccination programme has reduced cases of meningitis and septicaemia in young children by almost two-thirds. […] A new study by Public Health England (PHE) shows that infant vaccination against group B meningococcal disease (MenB) has resulted in a significant decline in cases of the disease in young children since the programme was introduced. […] MenB is one of the leading infectious killers in young children. The disease causes meningitis and septicaemia (blood poisoning) especially in young children and, while most recover with swift medical treatment, sadly around 1 out of 20 will die of the infection. […] PHEs study shows that by the third year of the programme, cases of MenB disease were 62% lower in children who were eligible for at least 2 doses of the vaccine. […] The MenB vaccine does not protect against all causes of meningitis and septicaemia, so parents need to remain vigilant of the signs and symptoms and seek medical advice if they are concerned. […] The vaccine BEXSERO aims to protect between 73 to 88% of MenB strains causing invasive disease such as meningitis and septicaemia in the UK.

• #4 MenB Vaccine (Meningococcal B Vaccine) | Vaccine Knowledge Project

  https://vaccineknowledge.ox.ac.uk/menb-vaccine

  Meningococcal disease is caused by the bacterium Neisseria meningitidis. […] The MenB vaccine protects against infection by group B meningococcal bacteria. […] Before the MenB vaccine was introduced, around 600 people a year in the UK, mainly babies and children, were infected by MenB. […] The vaccine does not contain any live bacteria and cannot cause meningococcal disease. […] Evidence has shown that the MenB vaccine provides some protection against gonorrhoea which is caused by gonococcal bacteria that are closely related to meningococcal bacteria. […] Bexsero, the MenB vaccine used in the UK, contains different proteins taken from group B Neisseria meningitidis bacteria. […] The combination of proteins was chosen to protect against the majority of MenB strains, rather than one specific strain.

• #5

  https://www.meningitis.org/meningitis/vaccine-information/meningococcal-group-b-vaccine

  Meningococcal vaccines protect against disease caused by meningococcal bacteria. There are several groups (called serogroups) of meningococcal bacteria that can cause disease. The most common disease-causing groups around the world are A, B, C, W, X and Y. […] The vaccines that protect against meningococcal group B (MenB) are protein vaccines. These vaccines contain proteins found on the surface of the bacteria. Like the other meningococcal vaccines, they trigger our immune system to produce antibodies that attack and fight off infection. The MenB vaccine provides protection against meningococcal disease, but doesn’t stop you from carrying the bacteria. […] Meningococcal vaccines are effective at preventing meningococcal disease. Research has shown that polysaccharide vaccines are 65%-83.7% effective. Conjugate vaccines are 66%-100% effective in protecting against meningococcal disease. […] No, available meningococcal vaccines are not live vaccines. They cannot cause meningococcal meningitis. Instead, meningococcal vaccines contain antigens (harmless pieces of the bacteria). These trigger your body’s immune system and cause it to produce antibodies that attack and kill the bacteria.

• #6 Meningococcal disease | The Australian Immunisation Handbook

  https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/meningococcal-disease

  Meningococcal disease is caused by the bacterium Neisseria meningitidis. The bacterium is commonly known as meningococcus. […] There are 13 known meningococcal serogroups, distinguished by differences in surface polysaccharides of the bacterium’s outer membrane capsule. Globally, serogroups A, B, C, W and Y most commonly cause disease. […] Several vaccines are available in Australia to reduce the risk of meningococcal disease. However, no single vaccine protects against all serogroups: […] 1 vaccine protects against meningococcal serogroup B — MenB vaccines. […] Although it is rare, IMD is a serious infection that can cause significant illness, disability and death. Vaccination programs have successfully reduced the incidence of IMD caused by serogroup C. […] The only brand of MenB vaccine registered and available in Australia is Bexsero, following with the discontinuation of Trumenba in 2024.

• #7 What is meningitis B – and why don’t older children get the vaccine? | University of Oxford

  https://www.ox.ac.uk/research/what-meningitis-b-%E2%80%93-and-why-don%E2%80%99t-older-children-get-vaccine

  Meningitis is an infection of the meninges, the lining around the brain and spinal cord. It can be caused by different bacteria and viruses, although bacterial infections are usually more serious. […] One of the bacteria which causes meningitis is called Neisseria meningitidis, also known as the meningococcus. This bacteria commonly lives harmlessly in peoples throats, but can cause devastating disease if it gets into the blood or spinal fluid. […] There are different types of this bacteria and the most common is known as type B what is often referred to as meningitis B, or MenB. […] Until recently, there was no vaccine against MenB. But in September 2015, the UK was the first country in the world to introduce a new MenB vaccine Bexsero, produced by GlaxoSmithKline into the routine NHS childhood immunisation programme.

• #8 Meningitis B | Student Health & Wellness | Dalhousie University

  https://www.dal.ca/campus_life/health-and-wellness/my-health/health-promotion/meningitis-b.html

  Meningococcal Meningitis (MenB) is an infection spread by direct contact with secretions from the nose and mouth of an infected person. The bacteria that can cause bacterial meningitis are spread by direct secretions (saliva or spit) from the nose and mouth, through activities such as kissing, sharing food, drinks, water bottles, toothbrushes, eating utensils, cigarettes and other smoking products/devices. […] While anyone can get bacterial meningitis, younger populations and students are often more susceptible due to communal living arrangements like university residences and shared housing, and behaviours and activities that result in the sharing of personal items. […] Meningitis B immunizations are not usually funded in most provinces or countries, including Nova Scotia, meaning it is not included in your routine childhood vaccine series. In most cases, childhood vaccinations would have included a meningitis vaccine that protected against MenACWY, but not MenB.

• #9 The Long Road to an Effective Vaccine for Meningococcus Group B (MenB)

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4306095/

  Neisseria meningitidis infection can cause life-threatening meningitis and meningococcal septicaemia. […] Recent attempts to create a universal MenB vaccine have been thwarted by the variability of the surface proteins of MenB and by the similarity of the MenB capsule to human glycoproteins. […] The simple reason is that the strategy used for the other meningococci doesn’t work for MenB. Vaccines for meningococcus groups A, C, W, and Y induce an immune response against the polysaccharide capsule around the bacterium. The capsular polysaccharide of MenB however, is structurally similar to certain abundant human glycoproteins like NCAM. It is therefore not a suitable immune target due to the risk of autoimmune damage through molecular mimicry. […] The barrier to developing a MenB vaccine thus has two facets: the difficulty in developing vaccines in general, and the specific challenge of creating a vaccine against a pathogen that mimics host molecules.

• #10 The Long Road to an Effective Vaccine for Meningococcus Group B (MenB)

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4306095/

  Current vaccines target the polysaccharide capsule, but the MenB capsule is composed of polymers of (28)-linked N-acetylneuraminic acid, which is also found on the human neural cell adhesion molecule NCAM. A vaccine directed at a host molecule might be expected either not to raise an immune response, or to cause autoimmunity. The MenB polysaccharide is not immunogenic in animal models or in humans. […] However, an immune response against (2-8)-linked N-acetylneuraminic acid was obtained in mice when it was administered conjugated to a tetanus toxoid. […] There is, therefore, little cross protection between MenB strains. […] Despite the risks of autoimmunity, it may be possible to use the capsular polysaccharide of MenB as an immunogen. […] OMV vaccines are the only MenB vaccines that have been proven to be protective in a general population setting.

• #11 The Long Road to an Effective Vaccine for Meningococcus Group B (MenB)

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4306095/

  Reverse vaccinology is a strategy for rational (or at least rigorous) vaccine design. […] The reverse vaccinology strategy identified a panel of proteins that seem to be ideal antigens: accessible to the immune system, immunogenic, inducing a protective response, present in all strains, and with minimal sequence variation. […] An alternative vaccine to 5CVMB, containing one fHbp from each family, is currently in clinical trials. […] What will the future hold for MenB vaccines? The roll-out of 4CMenB (Bexsero) is highly anticipated. […] With the advent of an effective vaccine against MenB, there is reason to be optimistic that invasive meningococcal disease will become a rarity in this country.

• #12

  https://www.sciencemediacentre.org/expert-reaction-to-menb-vaccine-for-meningitis-b-following-the-public-petition-calling-for-all-children-in-the-uk-to-be-given-the-vaccine/

  The new MenB vaccine, called Bexsero, represents that first vaccine of its kind to be used in humans, in which the protective components were selected by a computer-based predictive screen of the genetic profile of the meningococcus B bacterium. […] Bexsero was licensed in 2013 by the EMA without formal clinical trials on its efficacy. This is because meningococcal infection is a rare, howbeit devastating, disease and the classical double blind placebo controlled efficacy trial was utterly impractical. […] The highest incidence of MenB and other forms of meningococcal meningitis is in children less than 1 year old. […] The decision to vaccinate infants with the MenB Bexsero vaccine in the first instance is because they are the highest at-risk group for meningitis. […] There is no question that MenB disease, which can present as meningitis (inflammation of the lining of the brain) and/or septicaemia (blood poisoning), is a devastating disease and rightly feared by parents and health professionals alike, so we are lucky that there is a safe and effective vaccine to offer infants.

• #13 What to Know About the Meningitis B Vaccine

  https://www.healthline.com/health/meningitis/meningitis-b-vaccine

  Meningitis B is a type of meningococcal disease. Meningococcal diseases are a group of illnesses caused by the bacterium Neisseria meningitidis, which can be divided into 13 subcategories. Meningitis B is caused by the B subcategory (MenB). […] The meningitis B vaccine is made from proteins found on the outer part of the MenB bacterium. The exact proteins depend on which version of the vaccine you receive. Being exposed to these proteins stimulates your immune system to recognize the bacterium and teaches your body to protect itself from them. […] The MenB bacterial infection is passed between people through saliva and respiratory fluids. Activities like sharing drinks, kissing, or coughing can spread the bacterium. The meningitis B vaccine can help reduce transmission between people and prevent or manage outbreaks.

• #14 Meningococcal vaccines: Canadian Immunization Guide – Canada.ca

  https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-13-meningococcal-vaccine.html

  The majority of invasive meningococcal disease (IMD) is associated with Neisseria meningitidis serogroups A, B, C, Y and W […] Meningococcal disease is caused by an aerobic encapsulated diplococcus, N. meningitidis (meningococcus). Meningococcal serogroups are classified according to the immunogenic reactivity of the polysaccharide capsule. Almost all invasive meningococcal disease (IMD) is associated with serogroups A, B, C, Y, and W. Meningococcal serogroups A, B, and C cause the majority of disease worldwide and are responsible for most sporadic cases and outbreaks. […] Individuals with increased risk of meningococcal disease because of underlying medical conditions include the following: persons with functional or anatomic asplenia or sickle cell disease; persons with congenital immunodeficiencies such as complement, properdin, factor D, combined T and B cell immunodeficiencies or primary antibody deficiencies; persons with acquired complement deficiency due to receipt of the terminal complement inhibitor eculizumab (Soliris) or ravulizumab (ULTOMIRIS); individuals with HIV, especially if it is perinatally acquired. […] Meningococcal vaccines are recommended for individuals at high risk of IMD including those with underlying medical conditions and those who are at increased risk of exposure.

• #15 The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme–New challenges for public health – PubMed

  https://pubmed.ncbi.nlm.nih.gov/26433141/

  The United Kingdom is the first country to introduce Bexsero() (GSK Biologicals), a multicomponent, protein-based vaccine against meningococcal group B (MenB), into the national infant immunisation programme. […] Since the vaccine only protects against 73-88% of MenB strains causing invasive disease in England, clinical isolates and PCR-positive samples will require extensive characterisation by the Meningococcal Reference Unit (MRU) at Public Health England (PHE) in order to monitor vaccine effectiveness and identify potential vaccine failures. […] PHE is also conducting detailed clinical and epidemiological surveillance to assess the impact of the MenB immunisation programme on the morbidity and mortality associated with invasive meningococcal disease in infants and young children.

• #16 Meningococcal B vaccination: update | Advisory report | The Health Council of the Netherlands

  https://www.healthcouncil.nl/documents/advisory-reports/2022/10/12/meningococcal-b-vaccination-update

  Meningococcal B (MenB) is a very serious disease that can lead to meningitis and sepsis, and ultimately result in death. […] The vaccine is estimated to be 70 to 80% effective in the Dutch context. […] Compared to other vaccines, the MenB vaccine causes a relatively large number of temporary adverse events such as high fever, particularly in young children. […] The Council therefore recommends against the inclusion of the MenB vaccine in the RVP for the time being. […] There may be reason to reconsider this recommendation in the future, for example if the number of cases grows, the price of the vaccine falls considerably, or a new vaccine is developed.

• #17 MenB Vaccine (Meningococcal B Vaccine) | Vaccine Knowledge Project

  https://vaccineknowledge.ox.ac.uk/menb-vaccine

  The JCVI have recently suggested that the MenB vaccine should be used in a targeted programme to prevent gonorrhoea. […] Meningococcal disease (Neisseria meningitidis) and gonorrhoea (Neisseria gonorrhoeae) are closely genetically related, with evidence showing that the MenB vaccine provides some cross-protection against gonorrhoea (between 32.7% to 42%).

• #18 MenB: A gonorrhoea vaccine? — QueerHealth

  https://www.queerhealth.info/projects/menb

  MenB is a vaccine that has been shown to prevent gonorrhoea. […] Research shows that the MenB vaccine can prevent gonorrhoea. […] Evidence suggests that MenB is between 31% and 59% effective at preventing gonorrhoea. […] Estimates of the level of protection against gonorrhoea offered by MenB vary between studies but range between 31% and 59%. […] The first research to suggest that MenB can offer protection against gonorrhoea came from observational studies. […] In the case of MenB for gonorrhoea prevention, observational studies involve looking at the number of diagnoses of gonorrhoea infection among individuals who received the MenB vaccine to prevent meningococcal disease compared to the number of diagnoses among individuals who didn’t receive the vaccine. […] The JCVI made this recommendation, in part, because GBMSM currently have the highest rates of gonorrhoea diagnosis – so a targeted vaccination programme for GBMSM could make a big impact – and because the benefits of a programme like this one have been clearly modelled. […] A vaccination programme could help to slow the increase of antimicrobial resistance (AMR) in gonorrhoea. […] A vaccination programme could help address concerns about the development of antimicrobial resistance (AMR) in gonorrhoea.

• #19

  https://www.sciencemediacentre.org/expert-reaction-to-menb-vaccine-for-meningitis-b-following-the-public-petition-calling-for-all-children-in-the-uk-to-be-given-the-vaccine/

  The UK is the first country to introduce a national and publicly funded infant MenB immunisation programme in the world. […] It is really important that high quality research continues to be funded in order to address the remaining questions. […] However as yet we really dont know how effective it will be and if there are going to be any problems and this is a major area of ongoing research supported by the MRF.

• #20 Meningitis B: Symptoms, causes, treatment, and prevention

  https://www.medicalnewstoday.com/articles/meningitis-b

  Meningitis B is a serogroup of meningitis that occurs as a result of the Neisseria meningitidis bacteria. […] Meningitis B occurs when the bacteria break through the lining at the back of the throat, enter the bloodstream, and travel around the body. The bacteria can then infect the meninges and lead to bacteremia. […] MenB vaccines include Bexsero and Trumenba. […] Those aged 1623 years can get the MenB vaccine, as well as those who are at an increased risk of meningococcal disease, including: those at risk due to an outbreak; those who have a damaged spleen or those without a spleen, including those with sickle cell disease; those with complement component deficiency, which is a rare condition that affects the immune system; those taking complement inhibitor drugs, such as eculizumab or ravulizumab; microbiologists who work with N. meningitidis. […] Without treatment, meningitis B can lead to death.

• #21 Meningococcal Disease and the Men B Vaccine | AAFP

  https://www.aafp.org/family-physician/patient-care/prevention-wellness/immunizations-vaccines/disease-pop-immunization/meningococcal-disease-vaccine.html

  In 2014 and 2015, two vaccines offering protection against the B serotype of meningococcus were licensed. MenB-FHbp (Trumenba) and MenB-4C (Bexsero) are composed of novel protein or lipoprotein antigens. […] A serogroup B meningococcal (Men B) vaccine series may be administered to adolescents and young adults 16 through 23 years of age to provide short term protection against most strains of serogroup B meningococcal disease. […] The polysaccharide in the B strains of meningococcus is similar to a polysaccharide found in humans making Men B vaccines more challenging to develop. […] The development of these vaccines required sequencing of the bacterial genome to find proteins unique to the Neisseria bacterial wall that could be used as antigens to stimulate immunity in humans. […] Clinical trials of vaccine effectiveness are not practical or possible because the incidence of disease is low. Instead, vaccine efficacy was based on „complement mediated antibody killing” detected in serum of individuals who received the vaccines, a surrogate measure of protection.

• #22 Meningitis and Meningitis Vaccination Information

  https://www.steu.edu/student-life/wellness-center/health-services/meningitis.html

  Two meningococcal vaccines (MenACWY and MenB) provide protection against the serogroups that cause most meningococcal disease in the United States. […] The Meningitis vaccine that is required for the traditional undergraduates and residents is Meningitis ACWY, it does not protect against Meningitis B. […] Among 18 to 24-year-olds, college students are at an increased risk for sporadic and outbreak-associated MenB disease. […] During 2014-2016, six MenB disease outbreaks were reported on college campuses. […] Bacteria called Neisseria meningitidis cause meningococcal disease. […] There are five serogroups (types) of Neisseria meningitidis A, B, C, W, and Y that cause most disease worldwide. […] Three of these serogroups (B, C, and Y) cause most of the illness seen in the United States. […] Vaccines help protect against all three serogroups (B, C, and Y) of Neisseria meningitidis bacteria commonly seen in the United States. […] Teens and young adults (16 through 23 year olds) also may be vaccinated with a serogroup B meningococcal vaccine.

• #23 Meningococcal Vaccines – Medical Clinical Policy Bulletins | Aetna

  https://www.aetna.com/cpb/medical/data/300_399/0356.html

  ACIP recommends routine vaccination of persons aged 10 years or older at increased risk for meningococcal disease (dosing schedule varies by vaccine brand; boosters should be administered at 1 year after primary series completion, then every 2 – 3 years thereafter). […] MenB vaccination is not routinely recommended for all adolescents. Instead, ACIP recommends a 2-dose MenB series for persons aged 16 to 23 years on the basis of shared clinical decision-making, which refers to an individually based vaccine recommendation informed by a decision-making process between the health care provider and the patient or parent/guardian. The preferred age for MenB vaccination is 16 to 18 years. […] The ACIP recommends booster doses for previously vaccinated persons who become or remain at increased risk. For persons 10 years of age or older with persistent complement deficiencies (including patients using a complement inhibitor), anatomic and functional asplenia (including sickle cell disease), or are microbiologists routinely exposed to isolates of N. meningitidis, ACIP recommends single booster dose at 1 yr after completion of primary vaccination and every 2-3 yrs thereafter.

• #24 Meningitis B (MenB) vaccine | NHS inform

  https://www.nhsinform.scot/healthy-living/immunisation/vaccines/meningitis-b-menb-vaccine/

  The UK is the first country to introduce the MenB vaccine into its routine immunisation schedule for children. The vaccine is already offered to children in the UK with certain medical conditions and has also been used to contain outbreaks of MenB disease. It has been proved to be both safe and effective.

• #25 Arm Pain After a Meningitis Shot: Causes, Remedies, and Legal Options

  https://www.myvaccinelawyer.com/vaccine-injury-lawyer/resources/vaccine/injury/meningitis/arm-pain

  Meningococcal vaccines prevent meningococcal disease, a potentially severe illness caused by Neisseria meningitidis bacteria, which can notably affect the brain and spinal cord, potentially leading to dire consequences. […] Arm pain is common following the administration of meningococcal vaccines, as the Centers for Disease Control and Prevention (CDC) confirms. Meningitis shots, like many vaccinations, can cause some discomfort or pain at the injection site, typically described as a quick pinch or sting during the shot. Mild side effects such as soreness, redness, or swelling where the shot was given are common but usually last only a few days. […] When the meningitis vaccine is administered, the body recognizes its components as foreign and promptly initiates an immune response, which can result in pain at the injection site. While the reaction is normal, signifying an active immune system, the resultant arm pain can range from a mild, barely noticeable discomfort to a more pronounced and debilitating experience for some individuals.

• #26 Meningococcal B vaccination: update of the Health Council of the Netherlands | NITAG RESOURCE CENTER

  https://www.nitag-resource.org/resources/meningococcal-b-vaccination-update-health-council-netherlands

  Meningococcal B (MenB) is a very serious disease that can lead to meningitis and sepsis, and ultimately result in death. […] It is difficult to say precisely how effective the vaccine is, because the disease is rare. The vaccine is estimated to be 70 to 80% effective in the Dutch context. […] The MenB vaccine causes a relatively large number of temporary adverse events such as high fever, particularly in young children. This often leads to hospital admission and medical intervention. […] The Council therefore recommends against the inclusion of the MenB vaccine in the RVP for the time being. […] There may be reason to reconsider this recommendation in the future, for example if the number of cases grows, the price of the vaccine falls considerably, or a new vaccine is developed.

• #27 Meningococcal Disease and the Men B Vaccine | AAFP

  https://www.aafp.org/family-physician/patient-care/prevention-wellness/immunizations-vaccines/disease-pop-immunization/meningococcal-disease-vaccine.html

  Long-term studies have not yet been reported on either vaccine. […] There is a theoretic risk that Men B vaccines could cause autoimmune disease. […] For the MenB-FHbp vaccine, there were reports of 13 cases of autoimmune conditions in the 4,576 persons who received the MenB-FHbp vaccine and none in the 1,028 controls.

• #28 Meningococcal B vaccine – what you need to know: MedlinePlus Medical EncyclopediaLock

  https://medlineplus.gov/ency/article/007659.htm

  Meningococcal B vaccine can help protect against meningococcal disease caused by serogroup B. […] Meningococcal disease can cause meningitis (infection of the lining of the brain and spinal cord) and infections of the blood. […] Meningococcal disease is rare and has declined in the United States since the 1990s. However, it is a severe disease with a significant risk of death or lasting disabilities in people who get it. […] Meningococcal B vaccines are recommended for people 10 years or older who are at increased risk for serogroup B meningococcal disease. […] The same vaccine must be used for all doses. […] These vaccines may also be given to anyone 16 through 23 years old to provide short-term protection against most strains of serogroup B meningococcal disease. […] Meningococcal B vaccination should be postponed for pregnant women unless the woman is at increased risk and, after consultation with her health care provider, the benefits of vaccination are considered to outweigh the potential risks. […] As with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury, or death.

• #29 Meningococcal Vaccine (MPSV4, MCV4): Schedule and Side Effects

  https://www.webmd.com/children/vaccines/meningococcal-vaccine

  The vaccine may be given to pregnant women. However, since MCV4 and MenB are newer vaccines, there is limited data about their effect on pregnant women. […] There have been reports that a few people have been diagnosed with Guillain-Barre syndrome (GBS) after receiving MCV4. […] The current opinion is that even if there is a slight increase in the risk of GBS, it’s significantly outweighed by the risk of meningococcal disease without the vaccine.

• #30 Meningitis B: Symptoms, Outlook, and Vaccination

  https://www.healthline.com/health/meningitis/meningitis-b

  The best way to eliminate your risk of contracting N. meningitidis is by getting vaccinated. […] People ages 16 to 23 may also be recommended to get the MenB vaccine, which protects against bacterial serogroup B. […] Having certain medical conditions such as sickle cell disease or living in an area with a meningitis B outbreak increases risk. […] Meningitis B is a medical emergency that’s always treated in a hospital. […] Meningitis B is a form of bacterial meningitis. It’s a potentially deadly disease that can cause life-altering side effects. […] There’s a vaccine that significantly reduces or eliminates the risk of developing meningitis B. To have the most complete protection against meningococcal disease, two different vaccinations are required.

Zobacz więcej